The original trial answers the harder question
Before a drug is approved, its maker must establish that it can treat a condition and that its risks are understood. A generic version is not starting from zero: it contains the same active ingredient, the part of the medicine that produces its intended effect. Repeating large trials to rediscover that ingredient’s benefits would often tell regulators little that is new.
Instead, the key question is whether the generic delivers that ingredient to the body in a sufficiently similar way. Regulators also assess the product’s strength, dosage form, manufacturing quality, and other requirements before it can be sold.
Measuring what the body receives
In a bioequivalence study, researchers compare how the body absorbs the generic and the original. They measure the active ingredient’s concentration in blood over time. Two useful features are the overall exposure—the amount that enters circulation—and the rate at which levels rise. If these are sufficiently similar, the generic is expected to produce the same therapeutic effect under the same conditions.
This approach works because, for many medicines, matching the ingredient and its delivery makes repeating trials in patients unnecessary. It is a focused test of a specific link in the chain: does the substitute get the active drug to the body in much the same way?
Why the shortcut has limits
Similarity does not mean every tablet must contain identical inactive ingredients. Fillers, coatings, or colors can differ, but they cannot undermine the medicine’s performance or make it unsuitable for use. Some products are also harder to compare through ordinary blood-level studies, so their evidence requirements can differ.
The result is not “no testing.” It is a narrower test aimed at the main remaining uncertainty. Rather than asking thousands of patients again whether a well-established drug works, regulators can concentrate on whether the replacement delivers it comparably.
